Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants With Severe Combined Immunodeficiency (SCID) Receiving TCRαβ+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)

NCT03619551 is registered in ClinicalTrials.gov with Center for International Blood and Marrow Transplant Research as lead sponsor.

NCT NCT03619551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03619551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants With Severe Combined Immunodeficiency (SCID) Receiving TCRαβ+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)
Lead sponsor
Center for International Blood and Marrow Transplant Research
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 22, 2018
Completion date
December 1, 2028
Enrollment
56 (estimated)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

scid